SCHEMBL25589668

SCHEMBL25589668

COc1cc(-c2cnn(C3COC3)c2)ccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 2/20 0.53
▸ MKNK2 Q9HBH9 2/20 0.53
▸ EIF4E P06730 1/20 0.53
▸ TTK P33981 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ JAK2 O60674 3/20 0.48
▸ KIT P10721 2/20 0.48
▸ LRRK2 Q5S007 1/20 0.45
▸ MAP4K3 Q8IVH8 3/20 0.45
▸ KCNH2 Q12809 1/20 0.43
▸ ALK Q9UM73 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ GAK O14976 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22431103 0.88 TTK (0.54) MKNK1MKNK2TTKALDH1A1CYP3A4
SCHEMBL15651199 0.80 LRRK2 (0.55) MKNK1MKNK2EIF4ETTKJAK2
SCHEMBL12492042 0.78 ALDH1A1 (0.62) MKNK1MKNK2TTKALDH1A1CYP3A4
SCHEMBL30880505 0.76 KIT (0.49) MKNK1MKNK2EIF4ETTKJAK2
SCHEMBL25589670 0.74 TTK (0.59) TTK
SCHEMBL17024291 0.72 ALDH1A1 (0.57) TTKALDH1A1CYP3A4TSHRHSD17B10
SCHEMBL26598724 0.72 LRRK2 (0.46) MKNK1MKNK2EIF4ETTKJAK2
SCHEMBL29399235 0.71 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL48945 0.71 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL28862512 0.70 KIT (0.48) MKNK1MKNK2EIF4EJAK2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOIBIO INC. (KR) 2023-06-15 — — US disclosed
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOIBIO INC. (KR) 2023-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT TTK, TTBK1, TTBK2 MKNK1 146/4885MKNK2 162/4885EIF4E 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback